Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer
Journal for ImmunoTherapy of Cancer · 2023-11 · 11 (11) · e007805
DOI: 10.1136/jitc-2023-007805 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 08.11.2023. Verfasst von Kelly Boelaars und 16 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Cell Biology & Immunology, Amsterdam institute for Infection and Immunity, Cancer Center Amsterdam, Amsterdam UMC Location VUmc, Amsterdam,…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: LSH-TKI, Cancer Center, KWF.
Abstract (Originalsprache)
Background
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers. Despite the successful application of immune checkpoint blockade in a range of human cancers, immunotherapy in PDAC remains unsuccessful. PDAC is characterized by a desmoplastic, hypoxic and highly immunosuppressive tumor microenvironment (TME), where T-cell infiltration is often lacking (immune desert), or where T cells are located distant from the tumor islands (immune excluded). Converting the TME to an immune-inflamed state, allowing T-cell infiltration, could increase the success of immunotherapy in PDAC.
Method
In this study, we use the KPC3 subcutaneous PDAC mouse model to investigate the role of tumor-derived sialic acids in shaping the tumor immune landscape. A sialic acid deficient KPC3 line was generated by genetic knock-out of the CMAS (cytidine monophosphate N-acetylneuraminic acid synthetase) enzyme, a critical enzyme in the synthesis of sialic acid-containing glycans. The effect of sialic acid-deficiency on immunotherapy efficacy was assessed by treatment with anti-programmed cell death protein 1 (PD-1) and agonistic CD40.
Result
The absence of sialic acids in KPC3 tumors resulted in increased numbers of CD4 + and CD8 + T cells in the TME, and reduced frequencies of CD4 + regulatory T cells (Tregs) within the T-cell population. Importantly, CD8 + T cells were able to infiltrate the tumor islands in sialic acid-deficient tumors. These favorable alterations in the immune landscape sensitized sialic acid-deficient tumors to immunotherapy, which was ineffective in sialic acid-expressing KPC3 tumors. In addition, high expression of sialylation-related genes in human pancreatic cancer correlated with decreased CD8 + T-cell infiltration, increased presence of Tregs, and poorer survival probability.
Conclusion
Our results demonstrate that tumor-derived sialic acids mediate T-cell exclusion within the PDAC TME, thereby impairing immunotherapy efficacy. Targeting sialic acids represents a potential strategy to enhance T-cell infiltration and improve immunotherapy outcomes in PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Cell Biology & Immunology, Amsterdam institute for Infection and Immunity, Cancer Center Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands.
- Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
- JJP Biologics, Warsaw, Poland.
- Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.
- Molecular Cell Biology & Immunology, Amsterdam institute for Infection and Immunity, Cancer Center Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands y.vankooyk@amsterdamumc.nl.
ORCID-Profile: Kelly Boelaars, Ernesto Rodriguez, Nadine van Montfoort, Yvette van Kooyk
Förderung
- LSH-TKI
- Cancer Center
- KWF
- SPINOZANWO
Zitieren
APA
Boelaars, K., Goossens-Kruijssen, L., Wang, D., de Winde, C. M., Rodriguez, E., Lindijer, D., Springer, B., van der Haar Àvila, I., de Haas, A., Wehry, L., Boon, L., Mebius, R. E., van Montfoort, N., Wuhrer, M., den Haan, J. M. M., van Vliet, S. J., & van Kooyk, Y. (2023). Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer. Journal for ImmunoTherapy of Cancer, 11(11), e007805. https://doi.org/10.1136/jitc-2023-007805
Vancouver
Boelaars K, Goossens-Kruijssen L, Wang D, de Winde CM, Rodriguez E, Lindijer D, et al. Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer. Journal for ImmunoTherapy of Cancer. 2023;11(11):e007805. doi:10.1136/jitc-2023-007805
BibTeX
@article{Boelaars2023,
author = {Boelaars, Kelly and Goossens-Kruijssen, Laura and Wang, Di and de Winde, Charlotte M and Rodriguez, Ernesto and Lindijer, Dimitri and Springer, Babet and van der Haar Àvila, Irene and de Haas, Aram and Wehry, Laetitia and Boon, Louis and Mebius, Reina E and van Montfoort, Nadine and Wuhrer, Manfred and den Haan, Joke M M and van Vliet, Sandra J and van Kooyk, Yvette},
title = {Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {11},
pages = {e007805},
doi = {10.1136/jitc-2023-007805}
}
EUVIMED